Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, the cost of Mounjaro rose significantly in the UK from 1 September 2025, when Eli Lilly raised the list price across all doses — the highest dose moving from roughly £122 to around £330 per four-week pen. Private prices in the UK typically range from approximately £149 to £375 per month depending on dose and provider, and that shift reshaped what people see quoted online. Mounjaro (tirzepatide) is a prescription-only medicine that cannot be dispensed legally without a clinical assessment by a registered prescriber; any price you pay for private treatment should reflect that assessment, not just the pen itself.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Eli Lilly's UK list-price increase in autumn 2025 was reported widely and confirmed by the company. Before the change, a 15mg pen (four weekly doses) carried a list price of roughly £122; after 1 September 2025 that figure climbed to around £330, according to widely reported figures at the time. Lower doses moved by smaller but still notable amounts. This wasn't a quiet adjustment: it changed the baseline from which every private UK provider prices their supply.
It's worth pausing on a misconception that circulates online, that private clinics set Mounjaro's price independently, adding margins to a fixed manufacturer figure. In practice, list-price changes flow through the licensed UK supply chain and affect what pharmacies pay before a single consultation is written. The reason private prices vary between providers isn't mainly profit margin; it's what each provider includes alongside the pen.
For the fuller picture of where prices have moved month by month, the Mounjaro prices going up page tracks the trajectory, and if you're wondering whether any easing is expected, our page on whether the price is coming down addresses that question directly. If you're also weighing up whether NHS Mounjaro pricing is moving in the same direction, we cover that separately. The NICE technology appraisal TA1026, published December 2024 and updated September 2025, shaped NHS access in parallel, relevant context if you're weighing private cost against NHS eligibility.
A quoted monthly figure for Mounjaro rarely tells the whole story. Some providers charge separately for the initial consultation, the prescription, follow-up clinical reviews, dose-increase checks, and delivery. Add those together and a headline price that looked competitive can end up costing more than a higher advertised number that bundles everything in.
The items most commonly excluded from a headline price are: a clinical consultation fee (sometimes £25–£75 or more), an ongoing prescription charge per order, delivery (standard tracked or next-day), and aftercare access between doses. None of those are luxuries for a prescription medicine, a consultation is a legal requirement, and clinical follow-up is part of safe prescribing. If a quote doesn't mention them, it's worth asking before you commit.
At nume, one price covers all of it. We're not the cheapest option listed (that's a deliberate choice, not an oversight) because running a GPhC-registered pharmacy with same-day clinical review and seven-day aftercare has real costs. What you get for that is a service that doesn't add fees once you're in. You can see what's currently included on our treatment page, and the Mounjaro price breakdown page explains each component.
Mounjaro is a Prescription-Only Medicine. Under UK law it can only be supplied legally following a genuine clinical assessment by a qualified prescriber, and that assessment exists to protect you, not to add cost. When prices appear dramatically lower than the market range, or when a seller makes the pen available without any consultation, that's a red flag the MHRA has flagged publicly in relation to fake and illegally traded weight-loss medicines. In October 2025, enforcement teams raided the first illicit UK site manufacturing counterfeit tirzepatide pens; earlier operations seized roughly 20 million doses of illegally traded weight-loss medicines, worth an estimated £45 million. The MHRA's Yellow Card scheme lets you report a suspect seller directly.
The practical test isn't which provider quotes the lowest number. It's whether the provider is on the GPhC pharmacy register, whether a prescriber reviews your case personally, and whether genuine supply-chain sourcing is confirmed. Those things cost something. A small saving on a prescription medicine is not the measure that keeps you safe.
If you'd like to understand the cost context more before starting, the Mounjaro cost overview and our page on finding the most affordable legitimate route both set out what to look for. Our clinical team is also available for questions through our contact page.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.